Heart failure & cardiomyopathies
Association of Fibrate Use with Clinical Expression of Hypertrophic Cardiomyopathy
Authors' conclusion
The use of fibrates is associated with a lower incidence of clinical HCM expression. This association was also more prominent in those with obesity, unhealthy metabolic profiles and poor lifestyle behaviours.
Study context
- Population
- Patients without a history of hypertrophic cardiomyopathy (HCM) in a nationwide database, 2010–2017matched cohort
- Participants
- 412,823 vs 412,823
- Exposure
- Fibrate use vs no fibrate use
- Fibrate usersn = 412,823
- Fibrate-naïven = 412,823reference
- Outcome
- Incident clinical HCM expression
- Follow-up
- 5 years after a 1-year lag period
Methodological detailsnationwide database, 1:1 matched cohort
- Nationwide database
- 1:1 matched cohort
Main finding
As reported in the abstract
Incident clinical HCM · median follow-up 3.96 years
Fibrate use associated with lower risk of clinical HCM expression, adjusted HR
0.763 (0.630-0.924) (95% CI)
Observational data: associations, not effects.
Further findings
Clinical HCM, by obesity (subgroup)
- Fibrate use, BMI ≥25 kg/m², HR
- 0.719 (0.553-0.934) (95% CI)
- Fibrate use, abdominal obesity, HR
- 0.655 (0.492-0.872) (95% CI)
- No reduced risk in those without obesity
Clinical HCM, by TG and metabolic syndrome (subgroup)
- Fibrate use, TG ≥150 mg/dL, HR
- 0.741 (0.591-0.929) (95% CI)
- Fibrate use, metabolic syndrome, HR
- 0.750 (0.609-0.923) (95% CI)
- No lower risk in their counterparts
Clinical HCM, by lifestyle behaviours (subgroup)
- More prognostic benefit with fibrates in current smokers, alcohol consumers or those without regular physical activity
Original publication
Association of Fibrate Use with Clinical Expression of Hypertrophic Cardiomyopathy. ESC Heart Fail. Published 25 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →